Merck’s Endometrial Cancer Drug Cuts Risk Of Death By 32% – FDA Decision Due By June 2027

Separately, Merck reported positive Phase 3 Keynote-C93 results for its blockbuster Keytruda drug as a monotherapy in certain patients with advanced or recurrent endometrial…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)